• Something wrong with this record ?

Tailored antisense oligonucleotides designed to correct aberrant splicing reveal actionable groups of mutations for rare genetic disorders

HA. Wai, E. Svobodova, NR. Herrera, AGL. Douglas, JW. Holloway, FE. Baralle, M. Baralle, D. Baralle

. 2024 ; 56 (8) : 1816-1825. [pub] 20240801

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24019453

Grant support
RP-2016-07-011 DH | National Institute for Health Research (NIHR)

Effective translation of rare disease diagnosis knowledge into therapeutic applications is achievable within a reasonable timeframe; where mutations are amenable to current antisense oligonucleotide technology. In our study, we identified five distinct types of abnormal splice-causing mutations in patients with rare genetic disorders and developed a tailored antisense oligonucleotide for each mutation type using phosphorodiamidate morpholino oligomers with or without octa-guanidine dendrimers and 2'-O-methoxyethyl phosphorothioate. We observed variations in treatment effects and efficiencies, influenced by both the chosen chemistry and the specific nature of the aberrant splicing patterns targeted for correction. Our study demonstrated the successful correction of all five different types of aberrant splicing. Our findings reveal that effective correction of aberrant splicing can depend on altering the chemical composition of oligonucleotides and suggest a fast, efficient, and feasible approach for developing personalized therapeutic interventions for genetic disorders within short time frames.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019453
003      
CZ-PrNML
005      
20241024110727.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s12276-024-01292-1 $2 doi
035    __
$a (PubMed)39085356
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wai, Htoo A $u Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK $1 https://orcid.org/0000000235606980
245    10
$a Tailored antisense oligonucleotides designed to correct aberrant splicing reveal actionable groups of mutations for rare genetic disorders / $c HA. Wai, E. Svobodova, NR. Herrera, AGL. Douglas, JW. Holloway, FE. Baralle, M. Baralle, D. Baralle
520    9_
$a Effective translation of rare disease diagnosis knowledge into therapeutic applications is achievable within a reasonable timeframe; where mutations are amenable to current antisense oligonucleotide technology. In our study, we identified five distinct types of abnormal splice-causing mutations in patients with rare genetic disorders and developed a tailored antisense oligonucleotide for each mutation type using phosphorodiamidate morpholino oligomers with or without octa-guanidine dendrimers and 2'-O-methoxyethyl phosphorothioate. We observed variations in treatment effects and efficiencies, influenced by both the chosen chemistry and the specific nature of the aberrant splicing patterns targeted for correction. Our study demonstrated the successful correction of all five different types of aberrant splicing. Our findings reveal that effective correction of aberrant splicing can depend on altering the chemical composition of oligonucleotides and suggest a fast, efficient, and feasible approach for developing personalized therapeutic interventions for genetic disorders within short time frames.
650    _2
$a lidé $7 D006801
650    12
$a antisense oligonukleotidy $x terapeutické užití $x genetika $7 D016376
650    12
$a mutace $7 D009154
650    12
$a sestřih RNA $7 D012326
650    12
$a vzácné nemoci $x genetika $x farmakoterapie $7 D035583
650    _2
$a genetické nemoci vrozené $x genetika $x terapie $7 D030342
650    _2
$a morfolino $x terapeutické užití $x genetika $7 D060172
655    _2
$a časopisecké články $7 D016428
700    1_
$a Svobodova, Eliska $u Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $u Department of Clinical Immunology and Allergology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Herrera, Natalia Romero $u Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK
700    1_
$a Douglas, Andrew G L $u Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK $u Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
700    1_
$a Holloway, John W $u Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK
700    1_
$a Baralle, Francisco E $u Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK $u Fondazione Fegato, Area Science Park Basovizza, 34149, Trieste, Italy
700    1_
$a Baralle, Marco $u Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK $u International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano 99, 34149, Trieste, Italy
700    1_
$a Baralle, Diana $u Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK. d.baralle@soton.ac.uk
773    0_
$w MED00008294 $t Experimental & molecular medicine $x 2092-6413 $g Roč. 56, č. 8 (2024), s. 1816-1825
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39085356 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110721 $b ABA008
999    __
$a ok $b bmc $g 2201974 $s 1231426
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 56 $c 8 $d 1816-1825 $e 20240801 $i 2092-6413 $m Experimental & molecular medicine $n Exp Mol Med $x MED00008294
GRA    __
$a RP-2016-07-011 $p DH | National Institute for Health Research (NIHR)
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options